Turning Point Therapeutics Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Turning Point Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Turning Point Therapeutics stock.
View analyst ratings for Turning Point Therapeutics or view top-rated stocks.

Wall Street analysts have given Turning Point Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Turning Point Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Turning Point Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, May 11th 2021.
View our earnings forecast for Turning Point Therapeutics.

Turning Point Therapeutics, Inc. (NASDAQ:TPTX) announced its quarterly earnings data on Sunday, February, 28th. The company reported ($1.02) EPS for the quarter, missing the Zacks' consensus estimate of ($0.94) by $0.08.
View Turning Point Therapeutics' earnings history.

Turning Point Therapeutics' stock was trading at $40.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TPTX stock has increased by 90.5% and is now trading at $77.24.
View which stocks have been most impacted by COVID-19.

7 brokers have issued 12-month target prices for Turning Point Therapeutics' shares. Their forecasts range from $127.00 to $186.00. On average, they expect Turning Point Therapeutics' share price to reach $153.71 in the next year. This suggests a possible upside of 99.0% from the stock's current price.
View analysts' price targets for Turning Point Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Turning Point Therapeutics include Zai Lab (ZLAB), BioMarin Pharmaceutical (BMRN), Elanco Animal Health (ELAN), Ono Pharmaceutical (OPHLF), Grifols (GRFS), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Dr. Reddy's Laboratories (RDY), Jazz Pharmaceuticals (JAZZ), Maravai LifeSciences (MRVI), United Therapeutics (UTHR), Mirati Therapeutics (MRTX), BridgeBio Pharma (BBIO), Ultragenyx Pharmaceutical (RARE) and Arrowhead Pharmaceuticals (ARWR).
View all of TPTX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Turning Point Therapeutics investors own include NVIDIA (NVDA), Main Street Capital (MAIN), OPKO Health (OPK), The Boeing (BA), General Motors (GM), AbbVie (ABBV), Gilead Sciences (GILD), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ) and Livongo Health (LVGO).

(TPTX) raised $167 million in an IPO on Wednesday, April 17th 2019. The company issued 9,300,000 shares at $18.00 per share. Goldman Sachs, SVB Leerink and Wells Fargo Securities acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

Turning Point Therapeutics trades on the NASDAQ under the ticker symbol "TPTX."

Turning Point Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Pacer Advisors Inc. (0.00%). Company insiders that own Turning Point Therapeutics stock include Annette North, Athena Countouriotis, Brian Lee Baker, Carl L Gordon, Cormorant Asset Management, Lp, Jingrong Jean Cui, Mohammad Hirmand, Siegfried Reich, Simeon George and Yi Larson.
View institutional ownership trends for Turning Point Therapeutics.

TPTX stock was sold by a variety of institutional investors in the last quarter, including Pacer Advisors Inc.. Company insiders that have sold Turning Point Therapeutics company stock in the last year include Annette North, Athena Countouriotis, Brian Lee Baker, Jingrong Jean Cui, Mohammad Hirmand, Siegfried Reich, and Yi Larson.
View insider buying and selling activity for Turning Point Therapeutics or view top insider-selling stocks.

Shares of TPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TPTX stock can currently be purchased for approximately $77.24.

Turning Point Therapeutics has a market capitalization of $3.78 billion. The company earns $-72,130,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis.

Turning Point Therapeutics employs 142 workers across the globe.

The official website for Turning Point Therapeutics is www.tptherapeutics.com.

Turning Point Therapeutics is headquartered at 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121.

Turning Point Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The company can be reached via phone at 858-926-5251 or via email at [email protected]